TransCode Therapeutics (RNAZ) Short Interest Ratio & Short Volume $8.07 -1.30 (-13.87%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.70 -0.37 (-4.52%) As of 02/21/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TransCode Therapeutics Short Interest DataTransCode Therapeutics (RNAZ) has a short interest of 368,300 shares, representing 55.73% of the float (the number of shares available for trading by the public). This marks a 355.25% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.2, indicating that it would take 0.2 days of the average trading volume of 4.34 million shares to cover all short positions.Current Short Interest368,300 sharesPrevious Short Interest80,900 sharesChange Vs. Previous Month+355.25%Dollar Volume Sold Short$2.78 millionShort Interest Ratio0.2 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares700,000 sharesFloat Size660,900 sharesShort Percent of Float55.73%Today's Trading Volume135,792 sharesAverage Trading Volume4,340,440 sharesToday's Volume Vs. Average3% Short Selling TransCode Therapeutics? Sign up to receive the latest short interest report for TransCode Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRNAZ Short Interest Over TimeRNAZ Days to Cover Over TimeRNAZ Percentage of Float Shorted Over Time TransCode Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/2025368,300 shares $2.78 million +355.3%55.7%0.2 $7.56 1/15/202580,900 shares $258,071.00 -9.7%11.6%0.2 $3.19 12/31/202489,600 shares $301,952.00 +71.0%12.9%1.5 $3.37 12/15/202452,400 shares $388,808.00 +184.8%7.5%0.9 $7.42 11/30/202418,400 shares $6.97 million -91.5%2.7%0.4 $378.97 11/15/2024215,500 shares $73,205.35 -71.0%1.3%0.1 $0.34 10/31/2024743,600 shares $345,774.00 -39.1%4.3%0.4 $0.47 10/15/20241,220,000 shares $901,580.00 -11.6%7.1%0.6 $0.74 9/30/20241,380,000 shares $787,980.00 +52.5%8.0%0.7 $0.57 9/15/2024904,700 shares $234,407.77 +224.7%5.3%0.6 $0.26 Get the Latest News and Ratings for RNAZ and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/2024278,600 shares $73,383.24 +58.5%1.6%0.2 $0.26 8/15/2024175,800 shares $43,950.00 -89.3%1.0%0.2 $0.25 7/31/20241,640,000 shares $459,200.00 +6,539.7%9.6%1.1 $0.28 7/15/202424,700 shares $22,237.41 -85.2%0.4%0 $0.90 6/30/2024167,200 shares $168,036.00 -62.7%2.5%0.1 $1.01 6/15/2024448,500 shares $538,200.00 -56.0%6.9%0.4 $1.20 5/31/20241,020,000 shares $1.81 million +486.5%15.6%0.8 $1.78 5/15/2024173,900 shares $140,267.74 +16.2%2.7%0.1 $0.81 4/30/2024149,600 shares $90,822.16 +704.3%2.3%0.2 $0.61 4/15/202418,600 shares $9,975.18 -53.5%0.3%0 $0.54 3/31/202440,000 shares $27,320.00 -77.1%0.6%0.1 $0.68 3/15/2024174,800 shares $120,786.80 +71.4%2.7%0.3 $0.69 2/29/2024102,000 shares $71,869.20 -53.8%1.6%0.2 $0.70 2/15/2024220,900 shares $145,794.00 -70.8%3.4%0.4 $0.66 1/31/2024755,300 shares $521,912.30 +7,529.3%13.0%1.6 $0.69 1/15/20249,900 shares $49,500.00 -97.6%1.8%0 $5.00 12/31/2023405,000 shares $66,744.00 -7.4%N/A0.1 $0.16 12/15/2023437,500 shares $74,156.25 -31.3%2.0%0.1 $0.17 11/30/2023637,200 shares $156,751.20 +31.8%3.0%0.1 $0.25 11/15/2023483,300 shares $138,610.44 -63.4%2.5%0.1 $0.29 10/31/20231,320,000 shares $488,664.00 +562.0%7.4%0.2 $0.37 10/15/2023199,400 shares $86,100.92 +173.9%6.2%0 $0.43 9/30/202372,800 shares $36,596.56 -42.4%4.5%0 $0.50 9/15/2023126,400 shares $84,511.04 +418.0%7.1%0.1 $0.67 8/31/202324,400 shares $35,380.00 +1,255.6%1.7%0.2 $1.45 8/15/20231,800 shares $2,916.00 -87.8%0.1%0 $1.62 7/31/202314,700 shares $32,340.00 -85.5%2.5%0.1 $2.20 7/15/2023101,500 shares $257,810.00 +81.9%16.9%0.4 $2.54 6/30/202355,800 shares $128,340.00 +14.6%9.3%0.2 $2.30 6/15/202348,700 shares $129,055.00 +79.7%8.1%0.2 $2.65Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000” (Ad)Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?That's why we put together a 100% FREE 2025 Gold Guide to show you exactly how to protect and grow y 5/31/202327,100 shares $113,820.00 +22.1%4.4%0.2 $4.20 5/15/202322,200 shares $135,109.20 -96.6%N/A0.5 $6.09 4/30/2023653,200 shares $206,345.88 +2.7%5.6%0.4 $0.32 4/15/2023636,000 shares $250,965.60 +99.5%5.5%0.4 $0.39 3/31/2023318,800 shares $107,913.80 +21.0%2.8%0.2 $0.34 3/15/2023263,500 shares $91,618.95 -51.3%2.3%0.2 $0.35 2/28/2023541,400 shares $282,069.40 -42.9%4.7%0.1 $0.52 2/15/2023948,400 shares $635,428.00 +104.5%7.5%0.2 $0.67 1/31/2023463,700 shares $348,145.96 +0.8%5.3%0.2 $0.75 1/15/2023459,900 shares $281,458.80 -43.5%5.3%0.1 $0.61 12/30/2022814,100 shares $547,889.30 -22.5%9.4%0.3 $0.67 12/15/20221,050,000 shares $472,290.00 +2,849.4%12.1%0.4 $0.45 11/30/202235,600 shares $14,240.00 +368.4%0.4%0 $0.40 11/15/20227,600 shares $4,164.80 -96.5%0.1%0 $0.55 10/31/2022218,800 shares $147,033.60 +478.8%2.5%0.3 $0.67 10/15/202237,800 shares $41,995.80 -2.1%0.4%1.9 $1.11 9/30/202238,600 shares $42,460.00 +565.5%0.4%1.9 $1.10 9/15/20225,800 shares $6,728.00 -29.3%0.1%0.3 $1.16 8/31/20228,200 shares $9,840.00 +90.7%0.1%0.2 $1.20 8/15/20224,300 shares $5,547.00 -66.4%0.1%0.1 $1.29 7/31/202212,800 shares $18,176.00 +1.6%0.2%0.3 $1.42 7/15/202212,600 shares $16,632.00 +26.0%0.1%0.3 $1.32 6/30/202210,000 shares $12,600.00 +1.0%0.1%0.2 $1.26 6/15/20229,900 shares $12,573.00 -52.9%0.1%0.3 $1.27 5/31/202221,000 shares $38,640.00 -15.7%0.2%1.1 $1.84 5/15/202224,900 shares $56,025.00 -46.6%0.3%1.5 $2.25 4/30/202246,600 shares $127,218.00 +88.7%0.5%2.9 $2.73 4/15/202224,700 shares $70,814.90 -44.9%0.3%1.4 $2.87 3/31/202244,800 shares $129,024.00 +37.9%0.5%2 $2.88 3/15/202232,500 shares $70,200.00 -38.2%0.4%0.9 $2.16 2/28/202252,600 shares $112,038.00 -37.8%0.7%1.3 $2.13 2/15/202284,600 shares $181,044.00 -12.6%1.2%1.6 $2.14 1/31/202296,800 shares $222,640.00 -24.7%1.4%1.6 $2.30 1/15/2022128,500 shares $322,535.00 +51.4%1.8%1.6 $2.51 12/31/202184,900 shares $215,646.00 +0.7%1.2%0.7 $2.54 12/15/202184,300 shares $207,378.00 +157.0%1.2%0.3 $2.46 11/30/202132,800 shares $90,200.00 +32.8%0.5%0 $2.75 11/15/202124,700 shares $73,606.00 -86.7%0.4%0 $2.98 10/29/2021185,900 shares $526,097.00 -22.9%2.6%0 $2.83 10/15/2021241,100 shares $776,342.00 -47.1%3.4%0.1 $3.22 9/30/2021455,400 shares $1.36 million +1,350.3%6.4%0.1 $2.99 9/15/202131,400 shares $81,012.00 -39.7%0.4%0 $2.58 8/31/202152,100 shares $158,384.00 +128.5%0.7%0 $3.04 8/13/202122,800 shares $65,436.00 No Change0.4%0 $2.87 RNAZ Short Interest - Frequently Asked Questions What is TransCode Therapeutics' current short interest? Short interest is the volume of TransCode Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 368,300 shares of RNAZ short. 55.73% of TransCode Therapeutics' shares are currently sold short. Learn More on TransCode Therapeutics' current short interest. What is a good short interest percentage for TransCode Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 55.73% of TransCode Therapeutics' floating shares are currently sold short. Is TransCode Therapeutics' short interest increasing or decreasing? TransCode Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 368,300 shares, an increase of 355.3% from the previous total of 80,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is TransCode Therapeutics' float size? TransCode Therapeutics currently has issued a total of 700,000 shares. Some of TransCode Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TransCode Therapeutics currently has a public float of 660,900 shares. How does TransCode Therapeutics' short interest compare to its competitors? 55.73% of TransCode Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to TransCode Therapeutics: Surrozen, Inc. (6.18%), Rallybio Co. (1.72%), Cadrenal Therapeutics, Inc. (2.58%), Marinus Pharmaceuticals, Inc. (3.95%), ProMIS Neurosciences, Inc. (1.09%), Verrica Pharmaceuticals Inc. (4.43%), Lexaria Bioscience Corp. (3.77%), Akari Therapeutics, Plc (1.05%), Xilio Therapeutics, Inc. (1.01%), CytoMed Therapeutics Limited (3.95%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short TransCode Therapeutics stock? Short selling RNAZ is an investing strategy that aims to generate trading profit from TransCode Therapeutics as its price is falling. RNAZ shares are trading down $1.30 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against TransCode Therapeutics? A short squeeze for TransCode Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RNAZ, which in turn drives the price of the stock up even further. How often is TransCode Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RNAZ, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies Akari Therapeutics Short Interest Data Pulmatrix Short Interest Data Chemomab Therapeutics Short Interest Data Lexaria Bioscience Short Interest Data Cyclo Therapeutics Short Interest Data CytoMed Therapeutics Short Interest Data Allakos Short Interest Data Cardio Diagnostics Short Interest Data Daré Bioscience Short Interest Data Exicure Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RNAZ) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts